Subscribe
istock-652532896_filograph
filograph / iStockphoto.com
19 September 2018Americas

CRISPR Therapeutics unites with ViaCyte to treat diabetes

Gene-editing company CRISPR Therapeutics has partnered with regenerative medicine-focused ViaCyte to focus on diabetes treatments.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Vertex and CRISPR Therapeutics to develop gene-editing treatment
14 December 2017   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have revealed plans to jointly develop and commercialise an investigational gene-editing treatment.
Americas
ERS extends CRISPR influence with two licensing deals
20 September 2018   ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
Americas
CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology
13 November 2018   Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

More on this story

Americas
ERS extends CRISPR influence with two licensing deals
20 September 2018   ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
Americas
Vertex and CRISPR Therapeutics to develop gene-editing treatment
14 December 2017   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have revealed plans to jointly develop and commercialise an investigational gene-editing treatment.
Americas
CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology
13 November 2018   Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.

More on this story

Americas
ERS extends CRISPR influence with two licensing deals
20 September 2018   ERS Genomics and the Broad Institute of MIT and Harvard signed CRISPR licensing deals with Thermo Fisher Scientific on Tuesday, shortly before ERS expanded a separate agreement with Oxford Genetics.
Americas
Vertex and CRISPR Therapeutics to develop gene-editing treatment
14 December 2017   US-based Vertex Pharmaceuticals and CRISPR Therapeutics have revealed plans to jointly develop and commercialise an investigational gene-editing treatment.
Americas
CRISPR Therapeutics expands MaxCyte partnership into immuno-oncology
13 November 2018   Gene-editing company CRISPR Therapeutics has expanded its partnership with US-based MaxCyte, which focuses on cell-based medicines, into the immuno-oncology arena.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York